The background and the recent clinical trials of the current pneumococcal vaccine,
especially as they pertain to the institutionalized elderly, are described. Previous studies …

To evaluate the efficacy of the pneumococcal vaccine in the institutionalized elderly, we
designed a nonrandomized trial. We are following 998 patients institutionalized prior to the …

PURPOSE: To study the efficacy of pneumococcal capsular polysaccharide vaccine among
the elderly by use of a population-based intervention in one township, Varkaus, Eastern …

On March 28-30, 1988 the World Health Organization held a" Consultation on Immunization
of Elderly People with Polyvalent Pneumococcal Vaccine". The meeting was held in …

The effective prevention of Streptococcus pneumoniae infection has a renewed priority in an
era in which the emergence of antibacterial-resistant strains has the potential to further …

Pneumococcal vaccine effectiveness was assessed in a randomized trial among 1,686 old
people (mean age: 74, standard deviation: 4 years) living in 24 geriatric hospitals and 26 …

Pneumococcal infections are still a cause of high morbidity and mortality in elderly
populations. Since antibiotics are not wholly effective, vaccination should be performed. The …

Objectives: To compare the efficacy of the polysaccharide pneumococcal vaccine in older
adults between clinical trial and observational studies and to discuss the implications for …

Background. The 23-valent polysaccharide pneumococcal vaccine (PPV) is currently
recommended for elderly persons and persons who are at high risk of infection. However …

The burden of pneumococcal disease among elderly people is not widely known. In most
countries, the annual incidence of invasive pneumococcal disease in elderly people is most …